Torrent Pharmaceuticals reports audited Q4 and FY26 results, recommends dividend and QIP
Torrent Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Audited financial results for quarter and year ended March 31, 2026 approved with unmodified opinion.
- Proposed final equity dividend of ₹9 per equity share, record date fixed as May 29, 2026.
- Recommended shareholder approval for issuance of equity shares or convertible securities up to ₹5,000 crore via QIP or other modes at upcoming AGM.
Why it's rated major development: the year-on-year change is 27% (20% or more for adverse news)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Dated 22-May-26
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Torrent Pharmaceuticals
- Fundraise / allotmentNotableTorrent Pharmaceuticals allotted 4.19 crore shares to JB Chemicals shareholders on amalgamation
- Acquisition / mergerNotableTorrent Pharmaceuticals completes amalgamation with J. B. Chemicals & Pharmaceuticals
- Acquisition / mergerNotableTorrent Pharmaceuticals receives NCLT order approving J.B. Chemicals merger
- Acquisition / mergerNotableTorrent Pharmaceuticals' Scheme of Amalgamation with J. B. Chemicals sanctioned by NCLT
- Fundraise / allotmentMajor development· Adverse for the businessTorrent Pharmaceuticals audited FY26 results; recommends ₹9 final dividend
Other fundraise / allotment filings this fortnight
- Supreme Engineering allots 14,50,00,000 warrants at ₹2.60 on preferential basis
- Bajaj Finance Limited allots 5.74 crore warrants to Bajaj Finserv on 10 Nov 2026
- Bajaj Finance approves preferential issue of 5.74 crore warrants to Bajaj Finserv
- Chaman Metallics Limited announces H1 FY27 financial results and proposed Rights Issue
- Harmony Capital Services receives BSE approval for preferential issue of shares
- Kuber Udyog: open offer corrigendum, allotments of shares and warrants at ₹23.10
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.